However, as TNBC, relative to other breast cancer subtypes, generally has higher levels of tumor-infiltrating lymphocytes [158] and increased expression of immune checkpoint molecules, immunotherapy has become a promising avenue for PD-1/PD-L1 blockade treatments [159, 160]. The gene discussed is CD274; the disease is neoplasm.